<DOC>
	<DOCNO>NCT02092597</DOCNO>
	<brief_summary>The purpose study assess effect incretin-based antidiabetic therapy ( DPP-4 inhibitor GLP-1 agonist ) cardiovascular , gastrointestinal renal system detail mechanism underlie action system .</brief_summary>
	<brief_title>Safety Evaluation Adverse Reactions Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<mesh_term>Gliclazide</mesh_term>
	<criteria>Type 2 diabetes mellitus Metformin monotherapy stable dose last 3 month HbA1C 4875 mmol/mol ( IFCC ) BMI 2540 kg/m2 Age 3570 year ( woman postmenopausal ) Use ACE inhibitor ATII receptor blocker least 3 month enrollment eGFR &lt; 30 ml/min/1.73m2 ( MDRD ) Treatment incretin mimetics 3 month enrollment Chronic insulin therapy Chronic use loop diuretic , glucocorticoid , NSAID , immune suppressant , antimicrobial agent , chemotherapeutics , bile acid sequestrants ( colestyramin , colesevelam ) History pancreatic disease impair pancreatic function ( define need use pancreatic enzyme ) Active liver disease 3fold elevation liver transaminase ( ALT , AST ) Active malignancy History severe cardiovascular disease include acute coronary syndrome , stroke transient ischemic neurologic disorder previous 6 month , atrial fibrillation arrhythmia require chronic antiarrhythmic medication , chronic heart failure ( New York Heart Association grade III/IV ) History alcohol abuse , define &gt; 4 unit alcohol/day ( 32 g 40 ml 100 % alcohol ) History allergy GLP1 receptor agonist DPP4 inhibitor Any disease could interfere study procedure ( e.g . decrease mobility , mental incapacity ) Inability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>